GlassScriptPhysician profile
Ellen J Rosen
NPI 1891895959
$6,638.43
in general payments reported to CMS, 2019-2025
30 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $436 · 2021: $717 · 2022: $967 · 2023: $1,288 · 2024: $1,355 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,875 · Education: $16.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,874.76 |
| Education | $16.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,872.98 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,698.38 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $488.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $327.54 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $266.24 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $259.63 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $229.09 | 2019-2024 | Linzess |
| Qol Medical, LLC | $220.61 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $185.86 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $179.33 | 2019-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $95.16 | 2023-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $85.79 | 2019-2023 | Rebyota |
| Evoke Pharma, INC. | $71.84 | 2023-2025 | Gimoti |
| Celltrion USA INC. | $71.69 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $63.98 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $61.63 | 2023-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $59.61 | 2019-2022 | |
| Vivus LLC | $55.24 | 2023-2025 | Qsymia |
| Madrigal Pharmaceuticals | $53.10 | 2025 | Rezdiffra |
| Lilly USA, LLC | $51.67 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $39.23 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $37.09 | 2025 | Iqirvo |
| Pentax of America, INC. | $26.00 | 2025 | Pentax Medical, C2 Cryoballoon, Inspira |
| Ambu INC. | $23.60 | 2020 | |
| Biocon Biologics INC | $22.99 | 2025 | Yesintek |
| Genzyme Corporation | $21.50 | 2024 | |
| Medtronic, INC. | $20.92 | 2024 | Endoflip |
| Regeneron Healthcare Solutions, INC. | $18.72 | 2024 | Dupixent |
| Novo Nordisk INC | $16.25 | 2025 | Wegovy |
| Allergan, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.